



MORBIDITY AND MORTALITY WEEKLY REPORT

Epidemiologic Notes and Reports

July 3, 1981 / Vol. 30 / No. 25

Epidemiologic Notes and Reports 305 Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men – New York City and California 308 Cutaneous Larva Migrans in American

Tourists – Martinique and Mexico 314 Measles – U.S. Military

Kaposi's Sarcoma and *Pneumocystis* Pneumonia Among Homosexual Men – New York City and California

During the past 30 months, Kaposi's sarcoma (KS), an uncommonly reported malignancy in the United States, has been diagnosed in 26 homosexual men (20 in New York City [NYC]; 6 in California). The 26 patients range in age from 26-51 years (mean 39 years). Eight of these patients died (7 in NYC, 1 in California)—all 8 within 24 months after KS was diagnosed. The diagnoses in all 26 cases were based on histopathological examination of skin lesions, lymph nodes, or tumor in other organs. Twenty-five of the 26 patients were white, 1 was black. Presenting complaints from 20 of these patients are shown in Table 1.

Skin or mucous membrane lesions, often dark blue to violaceous plaques or nodules, were present in most of the patients on their initial physician visit. However, these lesions were not always present and often were considered benign by the patient and his physician.

A review of the New York University Coordinated Cancer Registry for KS in men under age 50 revealed no cases from 1970-1979 at Bellevue Hospital and 3 cases in this age group at the New York University Hospital from 1961-1979.

Seven KS patients had serious infections diagnosed after their initial physician visit. Six patients had pneumonia (4 biopsy confirmed as due to *Pneumocystis carinii* [PC]), and one had necrotizing toxoplasmosis of the central nervous system. One of the patients with *Pneumocystis* pneumonia also experienced severe, recurrent, herpes simplex infection; extensive candidiasis; and cryptococcal meningitis. The results of tests for cytomegalovirus (CMV) infection were available for 12 patients. All 12 had serological evidence of past or present CMV infection. In 3 patients for whom culture results were available, CMV was isolated from blood, urine and/or lung of all 3. Past infections with amebiasis and hepatitis were commonly reported.

Presenting complaint	Number (percentage) of patients
Skin lesion (s) only	10 (50%)
Skin lesions plus lymphadenopathy	4 (20%)
Oral mucosal lesion only	1 (5%)
Inguinal adenopathy plus perirectal abscess	1 (5%)
Weight loss and fever	2 (10%)
Weight loss, fever, and pneumonia	2 (10%)
(one due to Pneumocystis carinii)	3 U. P. 1997

TABLE 1. Presenting complaints in 20 patients with Kaposi's sarcoma

Kaposi's Sarcoma - Continued

Since the previous report of 5 cases of *Pneumocystis* pneumonia in homosexual men from Los Angeles (1), 10 additional cases (4 in Los Angeles and 6 in the San Francisco Bay area) of biopsy-confirmed PC pneumonia have been identified in homosexual men in the state. Two of the 10 patients also have KS. This brings the total number of *Pneumocystis* cases among homosexual men in California to 15 since September 1979. Patients range in age from 25 to 46 years.

Reported by A Friedman-Kien, MD, L Laubenstein, MD, M Marmor, PhD, K Hymes, MD, J Green, MD, A Ragaz, MD, J Gottleib, MD, F Muggia, MD, R Demopoulos, MD, M Weintraub, MD, D Williams, MD, New York University Medical Center, NYC; R Oliveri, MD, J Marmer, MD, NYC; J Wallace, MD, I Halperin, MD, JF Gillooley, MD, St. Vincent's Hospital and Medical Center, NYC; N Prose, MD, Downstate Medical Center, NYC; E Klein, MD, Roosevelt Hospital, NYC; J Vogel, MD, B Safai, MD, P Myskowski, MD, C Urmacher, MD, B Koziner, MD, L Nisce, MD, M Kris, MD, D Armstrong, MD, J Gold, MD, Sloan-Kettering Memorial Institute, NYC; D Mildran, MD, Beth Israel Hospital, NYC; M Tapper, MD, Lenox Hill Hospital, NYC; JB Weissman, MD, Columbia Presbyterian Hospital, NYC; R Rothenberg, MD, State Epidemiologist, New York State Dept of Health; SM Friedman, MD, Acting Director, Bur of Preventable Diseases, New York City Dept of Health; FP Siegal, MD, Dept of Medicine, Mount Sinai School of Medicine, City College of New York, NYC; J Groundwater, MD, J Gilmore, MD, San Francisco; D Coleman, MD, S Follansbee, MD, J Gullett, MD, SJ Stegman, MD, University of California at San Francisco; C Wofsy, MD, San Francisco General Hospital, San Francisco; D Bush, MD, Franklin Hospital, San Francisco; L Drew, MD, PhD, Mt. Zion Hospital, E Braff, MD, S Dritz, MD, City/County Health Dept, San Francisco; M Klein, MD, Valley Memorial Hospital, Salinas; JK Preiksaitis, MD, Stanford University Medical Center, Palo Alto; MS Gottlieb, MD, University of California at Los Angeles; R Jung, MD, University of Southern California Medical Center, Los Angeles; J Chin, MD, State Epidemiologist, California Dept of Health Services; J Goedert, MD, National Cancer Institute, National Institute of Health; Parasitic Diseases Div, Center for Infectious Diseases, VD Control Division, Center for Prevention Services, Chronic Diseases Div, Center for Environmental Health, CDC.

Editorial Note: KS is a malignant neoplasm manifested primarily by multiple vascular nodules in the skin and other organs. The disease is multifocal, with a course ranging from indolent, with only skin manifestations, to fulminant, with extensive visceral involvement (2).

Accurate incidence and mortality rates for KS are not available for the United States, but the annual incidence has been estimated between $0.02 \cdot 0.06$ per 100,000; it affects primarily elderly males (3,4). In a series of 92 patients treated between 1949 and 1975 at the Memorial Sloan-Kettering Cancer Institute in NYC, 76% were male, and the mean age was 63 years (range 23-90 years) at the time of diagnosis (5).

The disease in elderly men is usually manifested by skin lesions and a chronic clinical course (mean survival time is 8-13 years) (2). Two exceptions to this epidemiologic pattern have been noted previously. The first occurs in an endemic belt across equatorial Africa, where KS commonly affects children and young adults and accounts for up to 9% of all cancers (3). Secondly, the disease appears to have a higher incidence in renal transplant recipients (6-9) and in others receiving immunosuppressive therapy (10-12).

The occurrence of this number of KS cases during a 30-month period among young, homosexual men is considered highly unusual. No previous association between KS and sexual preference has been reported. The fulminant clinical course reported in many of these patients also differs from that classically described for elderly persons.

The histopathologic diagnosis of KS may be difficult for 2 reasons. Changes in some lesions may be interpreted as nonspecific, and other cutaneous and soft tissue sarcomas, such as angiosarcoma of the skin, may be confused with KS (13, 14).

That 10 new cases of *Pneumocystis* pneumonia have been identified in homosexual men suggests that the 5 previously reported cases were not an isolated phenomenon (1).

Vol. 30/No. 25

Kaposi's Sarcoma – Continued

In addition, CDC has a report of 4 homosexual men in NYC who developed severe, progressive, perianal herpes simplex infections and had evidence of cellular immunodeficiencies. Three died, 1 with systemic CMV infection. The fourth patient is currently undergoing therapy. It is not clear if or how the clustering of KS, pneumocystis, and other serious diseases in homosexual men is related. What is known is that the patients with *Pneumocystis* pneumonia described in the previous report showed evidence of impaired cellular immunity and previous or current CMV infection (1). Furthermore. serologic evidence of past CMV infection and active shedding of CMV have been shown to be much more common among homosexual men than heterosexual men attending a sexually transmitted disease clinic (15). A specific serologic association with CMV infection has been demonstrated among American and European patients with KS (16. 17) and herpes-type virus particles have been demonstrated in tissue culture cell lines from African cases of KS (18). It has been hypothesized that activation of oncogenic virus during periods of immunosuppression may result in the development of KS (19). Although immunosuppression often results in CMV infection, it is not yet clear whether CMV infection precedes or follows the above-mentioned disorders.

Although it is not certain that the increase in KS and PC pneumonia is restricted to homosexual men, the vast majority of recent cases have been reported from this group. Physicians should be alert for Kaposi's sarcoma, PC pneumonia, and other opportunistic infections associated with immunosuppression in homosexual men.

References

- 1. CDC. Pneumocystis pneumonia Los Angeles. MMWR 1981;30:250.
- 2. Safai B, Good RA. Kaposi's sarcoma: a review and recent developments. CA 1981;31:1-12.
- 3. Oettle AG. Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Un Int Cancr 1962;18:330-63.
- Rothman S. Remarks on sex, age, and racial distribution of Kaposi's sarcoma and on possible pathogenetic factors. Acta Un Int Cancr 1962;18:326-9.
- Safai B, Miké V, Giraldo G, Beth E, Good RA. Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications. Cancer 1980;45:1472-9.
- Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979;67:759-65.
- 7. Stribling J, Weitzner S, Smith GV: Kaposi sarcoma in renal allograft recipients. Cancer 1978; 42:442-6.
- Myers BD, Kessler E, Levi J, Pick A, Rosenfeld JB, Tikvah P. Kaposi sarcoma in kidney transplant recipients. Arch Intern Med 1974;133:307-11.
- 9. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 1979,27:8-11.
- Gange RW, Jones EW. Kaposi's sarcoma and immunosuppressive therapy: an appraisal. Clin Exp Dermatol 1978;3:135-46.
- 11. Klepp O, Dahl O, Stenwig JT. Association of Kaposi's sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi's sarcoma in Norway. Cancer 1978;42:2626-30.
- 12. Hoshaw RA, Schwartz RA. Kaposi's sarcoma after immunosuppressive therapy with prednisone. Arch Dermatol 1980:116;1280-2.
- 13. Girard C, Johnson WC, Graham JH. Cutaneous angiosarcoma. Cancer 1970;26:868-83.
- Rosai J, Sumner HW, Kostianovsky M, Perez-Mesa C. Angiosarcoma of the skin. A clinicopathologic and fine structural study. Hum Pathol 1976;7:83-109.
- Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981;143:188-92.
- Giraldo G, Beth E, Kourilsky FM, et al. Antibody patterns to herpesvirus in Kaposi's sarcoma: serologic association of European Kaposi's sarcoma with cytomegalovirus. Int J Cancer 1975; 15:839-48.
- Giraldo G, Beth E, Henle W, et al. Antibody patterns to herpesvirus in Kaposi's sarcoma. II. serological association of American Kaposi's sarcoma with cytomegalovirus. Int J Cancer 1978; 22:126-31.

Kaposi's Sarcoma - Continued

- 18. Giraldo G, Beth E, Haguenau F. Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. J Natl Cancer Inst 1972;49:1509-26.
- 19. Kapadia SB, Krause JR. Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma. South Med J 1977;70:1011-3.

Cutaneous Larva Migrans in American Tourists – Martinique and Mexico

Since October 19, 1980, the Parasitic Diseases Division, Center for Infectious Diseases, has received reports that 7 American tourists, who had vacationed briefly at Club Mediteranee seaside resorts in both Martinique and Mexico, returned with cutaneous larva migrans. The patients, 5 men and 2 women ranging in age from 33 to 38 years, resided in Massachusetts, Pennsylvania, Georgia, and Ohio, and were exposed on different dates.

(Continued on page 313)

	25th W	EEK ENDING		CUMULATIVE, FIRST 25 WEEKS					
DISEASE	June 27 1981	June 21 1980	MEDIAN 1976-1980	June 27 1981	June 21 1980	MEDIAN 1978-1980			
Aseptic meningitis	133	107	107	1,859	1,619	1,126			
Brucellosis	3	5	6	73	82	62			
Chickenpox	3,801	4,577	4,353	157,690	144,465	144,465			
Diphtheria	-	-	-	3	2	35			
Encephalitis: Primary (arthropod-borne & unspec.)	20	8	18	360	282	287			
Post-infectious	2	4	4	44	98	102			
Hepatitis, Viral: Type B	404	364	317	9,425	7,977	7,262			
Туре А	430	579	595	11,981	12,945	14,023			
Type unspecified	185	214	178	5,367	5,296	4,253			
Malaria	43	58	19	634	853	265			
Measles (rubeola)	85	463	924	2,292	11,224	20,679			
Meningococcal infections: Total	48	50	40	2,021	1,533	1.357			
Civilian	46	49	39	2,009	1,522	1,299			
Military	2	1	1	12	11	21			
Mumps	54	158	422	2,665	6,382	11,698			
Pertussis	23	26	26	482	524	524			
Rubella (German measles)	30	82	362	1,443	2,756	9,753			
Tetanus	4	4	1	27	29	29			
Tuberculosis	505	613	689	12,863	12,672	13,778			
Tularemia	6	7	4	87	70	62			
Typhoid fever	1	10	8	224	171	171			
Typhus fever, tick-borne (Rky. Mt. spotted)	57	39	48	436	318	299			
Venereal diseases:									
Gonorrhea: Civilian	18,174	20, 192	20,192	463,413	452,245	452,245			
Military	579	368	495	13,731	12,756	12,844			
Syphilis, primary & secondary: Civilian	610	488	452	14,248	12,387	11,575			
Military	6	5	5	178	151	146			
Rabies in animals	162	136	73	3,479	3,250	1,509			

TABLE I. Summary – cases of specified notifiable diseases, United States [Cumulative totals include revised and delayed reports through previous weeks.]

TABLE II. Notifiable diseases of low frequency, United States

The second se	CUM. 1981		CUM. 1981
Anthrax		Poliomyelitis: Total	-
Botulism	29	Paralytic	-
Cholera		Psittacosis (Mass. 1, Ohio 1, La. 1, Tex. 1, Colo. 1)	57
Congenital ruballa syndrome		Rabies in man	- 1
Leprosy (Upstate N.Y. 1)	103	Trichinosis (Conn. 1)	91
Leptospirosis (Ark. 2)	19	Typhus fever, flea-borne (endemic, murine) (Tex. 1)	16
Plague	5		

All delayed reports and corrections will be included in the following week's cumulative totals.

308

	ASEPTIC	BRU-		_		1	ENCEPHALI	TIS	HEPATI	TIS (VIRA	L), BY TYPE		
REPORTING AREA	MENIN	CEL	CHICKEN- POX	DIPHT	HERIA		imary	Post-in- fectious	В	A	Unspecified	MA	LARIA
	1981	1981	1981	1981	CUM. 1981	1981	1980	1981	1981	1981	1981	1981	CUM. 1981
UNITED STATES	133	3	3,801	-	3	20	8	2	404	4 30	185	43	634
NEW ENGLAND	3	-	607	-	-	-	2	-	14	12	10	3	34 1
Aaine J.H.	1	-	38 32	-	-	-	-		3	1	-		3
а.н. /t.	-	-	13	-	-		-	-	-	-	-	-	2
Aass.	1	-	253	-	-	-	1.2	1	4	3	10	2	17
R.I. Conn.	1	-	47 224	1	-			-	5	1	-	1	ģ
ID. ATLANTIC	6	-	510	1 - I	-	1	2	1	70	62	33	3	70
lpstate N.Y. I.Y. City	4	1	454 54	-	1	Ξ	-	12	13	9 13	12	3	20 23
I.J.	-	-	NN I		-		2	-	33	34	14	-	19
a.	2	-	2	-	-	1	-	1	7	6	1	-	8
N. CENTRAL	13	- 21	1,942	1	-	4	1	. e I.	65 26	60 20	10 5	3	28
hio nd.	3	-	319 137	- 24	-	1	1	-	12	11	4	-	6
I.	-	-	393	-	-	1	-	-	8	17	1	2	7
ich. is.	8 1	1	683 410	-	1.1	1	1		17	12	-	1	9
N. CENTRAL	3	1	24	_	- 1	2	-	-	20	9	4	1	19
inn.	-	-	9	-	-	1	- 2	12	4	4	1	1	8
o.	1 2	1	7	-	- 2 -	2	1.1		6	3	3		2
. Dak,	-	-	3	-	-	-		-	-	-	-	-	1
Dak.	-	-		-	- 2	-	1	12	1	- 2	1	-	1
ebr. ans.	Ξ.	-	1	-	-	1 -	-	-	-	-		-	5
ATLANTIC	16	2	258	-	1	1	100	-	87	52	22	1	72
el.	-	- *	22	-		-	1.2	2	5	2	3	-	1
d. C.	- 5 -	_	31 1	2	-		1.1		-	_	-		1
a.	1	-	13	-	-	-	-	-	4	2	-	-	11
. Va.	-	-	84	1			1	1	3	17	6	Ξ	3
.C. C.	2	- 2-	NN 12	-	-			-	13	3	2	-	ĩ
a. Ia.	12	1	10	1	1	1 <u>-</u>	1		16 32	10 24	11	1	8 26
		-		_	-	4	ı		35	22	8		4
.S. CENTRAL	12	-	76		-	-	-	-	15	11	4	-	-
enn.	7	-	NN	-	-	3		-	10	5	2	-	3
la. iss.	2	Ę	14	1	- 2	ī	1	-	6	5	-	-	1
S. CENTRAL	36	-	115			4	2	1	23	48	32	4	43
rk.	-	-	-	-	-	-	1		3	4	3	1	3
a. kla.	3 6	1	NN	Ξ	- 1	1	1	1	4	4	5 1	-	2
кта. Эх.	27	-	115	-	-	4	-	-	15	39	23	3	34
OUNTAIN	5	-	41	-	1	1	1.1	2	6	26	19	1	22
ont. aho	-	-	1.1	1	1	-		-	_	1	-	-	-
yo.	-	-	-	-		-	-	-	-	-	-	-	-
olo.	1	-	39	-	- 24	-	-	-	2	8	3	1	11
Mex. riz.	1	12	NN	_		ī	-		2	ś	19	-	1 4
tah	-	-	1	-	-	-	-	-	1	5	2	-	3
ev.	1	_	1	•			-	-	3	5	4	-	3
ACIFIC ash.	39 3	Ξ	228 193	2.1	1	3	2	-	84 5	139 7	47 3	27 1	342 18
eg.	-	-	4	-	-	-	-	-	9	7	-	1	9
alif.	35	-	3	- 1		3	2	1.1	67	124	44	25	311
laska awaii	-	-	5 23	2	1	-	- 2	-	3	1	-		1 3
uam R.	N A 3	NA	NA 23	NA _	2	NA _		-	N A 2	NA 11	N A 3	NA	1 8
.1.	-	-		-	-	-	1.50	-		-	-	-	2
c. Trust Terr.	NA	NA	NA	NA		NA	-	-	NA	NA	NA	NA	

TABLE III. Cases of specified notifiable diseases, United States, weeks ending

NN: Not notifiable. NA: Not available.

All delayed reports and corrections will be included in the following week's cumulative totals.

MENINGOCOCCAL INFECTIONS MEASLES (RUBEOLA) MUMPS PERTUSSIS RUBELLA TETANUS TOTAL REPORTING AREA CUM CUM. CUM. CUM. CUM. CUM. CUM. 1981 1981 1981 1981 1981 1981 1980 1981 1980 1981 1981 1981 UNITED STATES 85 2, 292 11,224 48 2,021 1,533 54 2,665 23 30 1,443 27 NEW ENGLAND -72 644 5 131 99 3 126 1 101 1 _ Maine 5 32 1 20 3 1 24 --33 _ N.H. -_ 4 316 -12 5 1 14 _ 35 _ _ -_ Vt. 1 226 6 13 -4 --Mass -54 2 22 47 32 34 _ 40 _ 1 _ **B.I.** _ 2 11 _ --2 17 ---_ 21 2 1 11 8 _ _ 1 Conn 37 27 MID. ATLANTIC 717 40 3,354 10 264 261 478 5 7 175 1 6 Upstate N.Y. ī ŝ 3 196 607 89 90 ż 3 76 73 N.Y. City 3 974 53 ž 1 52 3 45 70 2 46 N.J. 51 747 3 61 46 57 1 81 Pa. 34 418 1,026 4 69 44 ž 268 _ ž 10 _ E N CENTRAL 72 1,866 5 234 172 21 769 10 5 302 4 -Ohio . 15 229 2 84 64 113 _ 2 1 5 _ 105 _ Ind. 8 84 1 36 31 1 89 7 III. -21 275 2 57 27 13 151 1 _ 71 -Mich. _ -3 27 219 -53 39 1 288 1 31 Wis. -1.059 _ -1 1 4 11 4 128 -95 W.N. CENTRAL _ 1,232 94 171 1 73 8 --3 4 64 -Ā -ž Minn. 1.007 33 18 6 6 ī 1 lowa 20 18 _ 40 _ 4 1 6 2 28 27 -3 Mo. 1 62 28 --L N. Dak _ 1 1 S. Dak. _ 3 4 _ 1 -_ -_ _ Nebr. 1 80 -_ 3 1 Kans. _ 1 63 _ 11 7 _ 94 _ _ 59 _ S. ATLANTIC 8 318 1,710 467 357 5 з 346 3 3 131 6 Del. _ 3 -4 2 1 q 1 -1 -_ Md. _ 29 70 _ 1 47 33 1 1 D.C. _ _ 1 _ 1 1 1 _ --2 58 1 -5 Va. _ 294 _ 6 32 81 ı -W. Va. 8 19 12 _ 19 -7 --59 1 ĩź _ 2 69 _ _ N.C 113 -4 4 S.C. 139 63 44 _ 1 _ 9 _ 8 1 -25 -Ga. 101 770 33 1 2 79 64 97 44 12 _ 145 z ž 49 Fla. 197 337 72 E.S. CENTRAL 2 301 2 150 144 1 25 1 2 1 64 1 Ky. -51 43 46 ī 31 ī 14 -Tenn. _ _ 145 2 43 40 20 ı 10 _ -Ala. 2 2 48 37 _ 12 -1 21 1 Miss. 84 _ 16 21 -1 -_ 178 157 W.S. CENTRAL 25 795 899 11 348 2 1 3 122 5 Ark. 1 14 23 14 _ _ -1 1 La. _ 11 4 86 65 Ξ 3 _ q 2 -_ Okia 6 757 27 _ 1 16 1 25 212 2 153 1 3 112 788 117 83 Tex. 6 1 MOUNTAIN 3 32 324 2 71 56 2 95 1 -63 2 _ -Mont _ 1 _ 63 --5 4 -Idaho -1 _ -_ -4 4 -3 --2 ----Wyo. 1 1 3 8 -1 _ 17 31 14 39 -26 _ Colo 9 _ 7 2 _ N. Mex. -11 6 1 9 -21 -17 Ariz. 4 242 16 -1 --Utah 46 l 2 2 14 5 3 16 _ Nev 10 3 -4 _ 11 _ 7 _ PACIFIC 7 276 894 6 262 202 14 459 3 9 451 5 Wash -165 _ 51 34 1 129 1 1 59 Orag -_ -3 38 39 1 55 -30 7 719 6 165 127 2 5 Calif 270 11 255 8 357 Alaska -5 -4 2 5 _ --_ _ ı Hawaii 2 -4 15 _ 5 _ -NA 5 17 NA 6 NA NA Guarr 4 -1 195 89 _ 9 93 2 2 1 3 PR. 3 1 ٤, V.I. 4 6 --Pac. Trust Terr. _ 1 _ NA NA 4 NA NA 6

TABLE III (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending June 27, 1981 and June 21, 1980 (25th week)

NA: Not available

All delayed reports and corrections will be included in the following week's cumulative totals.

REPORTING AREA	1981	RCULOSIS	REMIA				borne)	VENEREAL DISEASES (Civilian)								
NEW ENGLAND	1981				FEVER		USF)		GONORRHEA		SY	PHILIS (Pri	. & Sec.)	(in Animala)		
NEW ENGLAND		CUM. 1981	CUM. 1981	1981	CUM. 1981	1981	CUM. 1981	1981	CUM. 1981	C U M. 1980	1981	CUM. 1981	CUM. 1980	CUM. 1981		
	505	12,863	87	7	224	57	436	18,174	463,413	452,245	610	14,248	12,387	3,479		
	23	360	1	-	12	-	5	477	11,492	11,671	13	313	269	13		
Maine N.H.	- 21	23	-	-	1	-	-	12	568 383	685 383	-	2	4	- 7		
Vt.	12	11	- 2 -	1	- 2 -	-		15	200	277	-	10	3	1		
Mass.	16	203	-	-	7	_	3	242	4,670	4,788	13	207	151	1		
R.I.	-	21	-	-	-	-	-	31	602	699		18	15	-		
Conn.	7	93	1	-	4	-	2	172	5,069	4,839		63	95	4		
MID. ATLANTIC	92	2,090	10	-	39	1	9	2,111	53,771	48,916	87	2,165	1,801	28		
Upstate N.Y. N.Y. City	5	352	10	1	22	-	2	368	9,189	8,834	18	207	143	24		
N.J.	22	789 468		-	22	ī	2	900 430	21,454 10,562	19,143 9,099	45	1,307	1,191 230			
Pa.	20	481	-	-	4	-	2	413	12,566	11,840	13	368	237	4		
E.N. CENTRAL	50	1,707	1	-	14	7	17	1,988	69,256	69,920	37	889	1,183	441		
Ohio	13	325	-	-	1	7	15	584	25,135	18,791	-	128	199	32		
Ind.	5	148	-	-	-		2	127	6,513	6,641	3	103	92	33		
III. Mich.	26	690 455	ī	12	6		-	454	16,359	21,980 15,652	32	443	665 180	348		
Wis.	6	89	-	-	2	-		223	6,253	6,856	-	47	47	25		
W.N. CENTRAL	27	472	7	-	8	5	13	1,031	22,380	20.092	14	275	149	1,490		
Minn.	12	84	-	-	2	-	-	98	3,495	3,430	- 4	101	54	270		
lowa	-	. 49	-	-	2	-	_	110	2+405	2,242	-	13	8	480		
Mo. N. Dak.	10	198	6	-	1	5	8	422 B	10,285	8,419	10	138	72	120		
S. Dak.	1	20 36	- 2 -	-	ī	-	- 2	33	314 635	301 630		2	2	239		
Nebr.	-	15	1	-	î	-	1	123	1,737	1,691	-	3	ŝ	111		
Kans.	4	70	-	-	1	-	4	237	3,509	3,379	-	14	1	103		
S ATLANTIC	104	2,885	8	2	34	35	255	4,703	114,308	111,127	110	3,743	2,943	199		
Del. Md.	15	41 293	* 1	1		2	2	72	1,686	1,538 11,726	6	285	207			
D.C.	8	172		-	11	- 1	32	215	7,150	7,863	â	311	201	- -		
Va.	12	293	-	-	i	3	32	436	10,522	9,438	ă	347	261	34		
W. Va.	10	96	-	-	4	1	4	85	1,723	1,457	-	9	12	9		
N.C. S.C.	21	488	1	-	1	15	94	826	17,796	16,316	14	298	218	2		
Ga.	-	275 453	2	- 2	2	6	60 25	487	10,727	10,518 21,051	28	252 967	151	14 93		
Fla.	37	774	Ē	1	14	-	6	1,163	29,207	31,220	41	1,267	1,023	39		
E.S. CENTRAL	53	1,130	2	-	5	5	45	1,150	38,423	36,833	27	922	1,009	233		
Ку.	18	309	2	-	_	-	2	175	4,948	5,389	1	44	72	67		
Tenn. Ala.	5 21	363	-	-	1	3	32	445 209	14,581	12,975	9	364	407	129		
Miss.	21 9	311 147	-	-	2 2	2	2 9	321	11,664	7,528	9	263	208 322	37		
W.S. CENTRAL	64	1.411	43	3	21	2	82	2,388	61,623	58,762	176	3.473	2,397	653		
Ark.	11	141	20	_			15	267	4,269	4,448	- 4	67	79	91		
La.	14	269	2	-	-	-	-	254	9,756	10,381	62	796	574	20		
Okia. Tex.	3 36	161	12	3	3	2	55 12	338 1,529	6,631 40,967	5.812 38,121	3 107	84 2,526	50	123		
MOUNTAIN	18	358						746								
MOUNTAIN Mont	18	358	12	-	17	2	9	25	18,472 642	17,331	24	371	285	98 58		
Idaho		6	2	1.1		-	2	59	780	794	6	15	9	28		
Wya.	1	6	1	-	-	-	2	13	413	509	- 1	7	7	5		
Colo. N. Mex.	1	42	2	12	4	-	- 1	180	4,909	4,641	-	106	78	10		
N. Mex. Ariz.	11	68 157	1	-	9	121		100	2,023	2,228	11	71	50 93	16		
Utah	2	197	1	-		_	-	42	864	809	3	14	93 7	7		
Nev.	-	37	ī	-	-	-	1	196	3.102	3,091	ź	69	40	2		
PACIFIC	74	2,450	3	2	74	-	1	3,580	73,688	77,593	122	2,097	2,351	324		
Wash.	-	192	1	-	5	-		184	5,895	6,361	-	66	118	-		
Oreg. Calit	6	94 2,064	5	-	3	-	ī	138	4,647	5,440	1 20	45	54	3		
Alaska	67	34	2	2	66	-	- 1	76	1,849	62,327 1,859	120	1,943	2,084	308		
Hawaii	1	66	-	-	-	-		46	1,414	1,606	2	38	91	13		
Contraction of the																
Guam P.B.	NA	149	-	NA	- 3	NA	-	NA 69	47	70	NA	-	4			
v.i.	-	149	-	-	1	-	_	6	1,599	1,270	12	327 7	259 10	41		
	NA	23	-	NA	-	NA	-	NA	134	199	NA	<u>'</u>				

TABLE III (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending June 27, 1981 and June 21, 1980 (25th week)

Pac. Trust Terr. NA: Not available.

All delayed reports and corrections will be included in the following week's cumulative totals.

TABLE IV. Deaths in 121 U.S. cities,* week ending June 27, 1981 (25th week)

		ALL CA	USES, BY	AGE (YE	ARS)					ALL CA	USES, BY	AGE (YE	ARS)		
REPORTING AREA	ALL Ages	>65	45-64	25-44	1-24	<1	P&I** TOTAL	REPORTING AREA	ALL AGES	≥65	45-64	25-44	1-24	<1	P&1* Tota
NEW ENGLAND	665	414	168	46	19	18	35	S. ATLANTIC	1,110	635	315	90	44	26	54
Boston, Mass.	177	94	51	17	7	8	12	Atlanta, Ga.	149	75	55	13	6		3
Bridgeport, Conn.	61 35	39 30	16	5 1	-	1	11	Baltimore, Md. Charlotte, N.C.	159	68 42	59 16	17	11	4	4
Cambridge, Mass. Fall River, Mass.	23	18	5	1	-		2	Jacksonville, Fla.	101	63	19	ú	3	5	6
Hartford, Conn.	49	29	13	2	3	2	-	Miami, Fla.	108	58	39	- 7	2	ź	4
Lowell, Mass.	17	7	9	-	í	-	-	Norfolk, Va.	60	32	20	3	2	3	2
Lynn, Mass.	18	12	5	1	-	-	-	Richmond, Va.	75	45	18	5	4	3	7
New Bedford, Mass		18	6	2	-	-	2	Savannah, Ga.	39	22	12	3	2		27
New Haven, Conn. Providence, R.I.	37	26 43	7 19	17	1	2	2	St. Petersburg, Fla. Tampa, Fla.	96 79	85 53	6 20	2	2	1	3
Somerville, Mass.	10	45	3	-	ĩ	3	2	Washington, D.C.	149	71	45	21	5	7	é
Springfield, Mass.	46	28	11	6		1	2	Wilmington, Del.	30	21	6	2	í	-	
Waterbury, Conn.	28	16	8	2	1	ī	-			-					
Worcester, Mass.	62	48	11	2	1	-	2								
								E.S. CENTRAL	676	420	174	39	16	27	24
		S			~ 1	-		Birmingham, Ala.	109	69	31 11	4	1	4	2
MID. ATLANTIC Albany, N.Y.	44	1.624	613 12	178	81 2	79 5	101	Chattanooga, Tenn. Knoxville, Tenn.	57 45	41 29	10	3	3	- 2	ĩ
Allentown, Pa.	20	13	7	_	-	-	-	Louisville, Ky.	108	70	26	5	3	4	5
Buffalo, N.Y.	100	60	30	5	4	1	12	Memphis, Tenn.	165	98	47	9	4	ż	5
Camden, N.J.	22	16	5	í	-	-	ĩ	Mobile, Ala.	50	28	12	3	2	5	3
Elizabeth, N.J.	31	23	7	1	-	-	-	Montgomery, Ala.	39	28	4	1	-	6	-
Erie, Pa.†	33	19	13	-	1	-	1	Nashville, Tenn.	103	57	33	9	3	1	8
Jersey City, N.J.	44	30	10	3	-	1	1								
N.Y. City, N.Y. Newark, N.J.	1,325	857 28	275	115	43	35 13	42		1,265	735	304	108	59	59	28
Paterson, N.J.	34	20	11	6	ĩ	13	4	W.S. CENTRAL Austin, Tex.	49	32	10	2	3	2	-
Philadelphia, Pa.	390	226	115	23	12	14	24	Baton Rouge, La.	44	28	12	3	ĩ	-	4
Pittsburgh, Pa. 1	75	47	22	2	3	1	4	Corpus Christi, Tex.	43	27	6	4	ī	5	1
Reading, Pa.	50	36	11	1	2	-	4	Dallas, Tex.	164	91	32	16	8	17	-
Rochester, N.Y.	119	91	20	3	1	4	2	El Paso, Tex.	60	26	19	5	4	6	3
Schenectady, N.Y. Scranton, Pa.†	24	18	4	2		-		Fort Worth, Tex.	82	52	19 92	7	3 27	1	7
Syracuse, N.Y.	25 76	17 44	24	1	1 5	2 2	1	Houston, Tex.	370 93	205	23	34	3	12	3
Trenton, N.J.	34	19	13	ź	-	-	1	Little Rock, Ark. New Orleans, La.	115	57	39	13	2	4	
Utica, N.Y.	17	14	11	ž	-	1	-	San Antonio, Tex.	145	91	30	14	5	5	6
Yonkers, N.Y.	36	25	5	4	2	-	4	Shreveport, La. Tulsa, Okia.	30 70	18 51	11	4	2	1 2	1
E.N. CENTRAL	2, 247	1,337	573	166	96	75	80								
Akron, Ohio	99	67	22	3	4	3	2	MOUNTAIN	601	358	124	51	46	22	18
Canton, Ohio	49	37	10	-	-	2	2	Albuquerque, N. Mex.	76	35	19	9	13	-	-
Chicago, III.	492	281	124	44	20	23	10	Colo. Springs, Colo.	46	32	7	1	5	1	4
Cincinnati, Ohio	150	89	42	12	3	4	16	Denver, Colo.	112	66	29	8	6	3	4
Cleveland, Ohio	191	111	52	13	13	2	6	Las Vegas, Nev.	66 15	29 13	18	8 1	8	3	
Columbus, Ohio Dayton, Ohio	129	79 67	30 29	6	5	2	1	Ogden, Utah	123	71	24	12	10	6	2
Detroit, Mich.	272	134	80	34	12	12	16	Phoenix, Ariz. Pueblo, Colo.	29	22	3	3	-	ĭ	4
Evansville, Ind.	44	29	14	-	1		-	Salt Lake City, Utah	58	37	10	4	2	5	2
Fort Wayne, Ind.	45	28	11	1	- 4	1	3	Tucson, Ariz.	76	53	13	5	2	3	-
Gary, Ind.	21	8	5	6	2	-	2								
Grand Rapids, Mich		25	10	3	3	5			1 015	1 150	402	1.2.2		6.2	84
Indianapolis, Ind.	150 38	86 21	44	10	7	3 2	1	PACIFIC	1,815	1,159	403 3	132	68 1	53	1
Madison, Wis. Milwaukee, Wis.	113	78	28	5	2	2	2	Berkeley, Calif. Fresno, Calif.	89	47	22	ģ	9	2	2
Peoria, III.	33	18	- 9	3	2	í	3	Glendale, Calif.	38	29	7	1	1	-	2
Rockford, III.	38	22	i	5	3	1	5	Honolulu, Hawaii	67	35	21	6	3	2	4
South Bend, Ind.	58	34	14	6	3	1	1	Long Beach, Calif.	84	44	26	5	4	5	1
Toledo, Ohio	91	66	17	5	2	1	4	Los Angeles, Calif.	482	324	59	35	14	10	17
Youngstown, Ohio	81	57	18	4	-1	1	1	Oakland, Calif. § Pasadena, Calif.	85 38 119	55 30 76	10 7 31	6 - 9	3	3	3 5 2
W.N. CENTRAL	674	404	172	41	33	24	19	Portland, Oreg. Sacramento, Calif.	75	47	13	6	17	2 2	5
Des Moines, Iowa	68	38	20	1	5	4	1	Sacramento, Calif. San Diego, Calif.	142	95	30	7	3	7	4
Duluth, Minn.	14	11	3	-	1	1		San Francisco, Calif.	146	89	32	20	ĩ	4	6
Kansas City, Kans.	36	20	10	5	1	-	1	San Jose, Calif.	207	132	46	14	10	5	21
Kansas City, Mo.	109	69	24	5	2	9	2	Seattle, Wash.	129	75	30	9	8	7	3
Lincoln, Nebr.	29	17	8	2	2	-	3	Spokane, Wash.	55	38	12	1	2	2	7
Minneapolis, Minn.	75	50	11	8	5	1	1	Tacoma, Wash.	37	27	6	2	1	1	1
Omaha, Nebr.	83	51	20	5	5	2	1								
St. Louis, Mo. St. Paul, Minn.	141 55	78 37	44 12	7 2	9 2	3	6	707.4	11,628	7.096	. 844	851	462	383	443
St. Paul, Minn. Wichita, Kans.	55	33	20	6	2	2 3	4	TOTAL		.,			102	202	
monita, realis.	04	22	20		4	2	1								

*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

**Pneumonia and influenza

tBecause of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

ttTotal includes unknown ages.

§Data not available this week. Figures are estimates based on average percent of regional totals.

Vol. 30/No. 25

MMWR

Cutaneous Larva Migrans — Continued

Clinical findings were similar in all cases; 1 case report follows:

On February 1, 1981, a 38-year-old male, in generally good health, returned to his home in Philadelphia following a one-week stay in Martinique at a limited-access resort. Six days after his return, multiple, subcutaneous, reddish-purple, pruritic lesions erupted on the soles of both feet. Within 12 hours, it was painful for him to stand, and within 24 hours, serpiginous lines appeared (contiguous with the original lesions) and spread over the soles and onto the dorsum of his feet.

A dermatologist and an infectious disease physician diagnosed cutaneous larva migrans. The patient was treated with 1.0 g thiabendazole (Mintezol) twice a day for a total of 4 doses, and because of the relatively heavy infection with marked secondary swelling and inflammation, 30 mg prednisone was also given daily.

Initial improvement was noted, and within 12-18 hours after the first dose of thiabendazole, no further extension of the serpiginous lines was seen. Steroid therapy was stopped after 3 days. Five to six days after initial therapy, large vesicles formed at the site of the initial lesions and walking became quite painful. Mild periorbital swelling was noted at this time, but a differential count (48 hours after prednisone had been stopped) revealed no eosinophilia. Prednisone was reinitiated (topically and systematically) with gradual (5-6 days) resolution of the lesions.

Reported by DJ Wyler, MD, C Panosian, MD, S Gorbach, MD, Tufts University School of Medicine, Boston; DJ Eskin, MD, Abington, Pennsylvania; LK Feinerman, MD, Atlanta, Georgia; Parasitic Diseases Division, Center for Infectious Diseases, CDC.

Editorial Note: Cutaneous larva migrans (creeping eruption) is a form of dermatitis caused by the burrowing of certain types of nematode larvae and characterized by a progressive, linear, papulo-vesicular, pruritic lesion which marks the migratory course of the invading larva (1). Human exposure results from skin contact with warm, moist sandy soil containing filariform larvae of hookworms originating from the excreta of dogs and cats. The most common causative agent in the southern United States and, perhaps in the Caribbean, is the dog and cat hookworm Ancylostoma braziliense whose range includes the Atlantic and Gulf coastal regions from Maryland to Texas. Larvae of nonhuman species of Strongyloides and some other species of skin-penetrating nematodes may also produce the syndrome. After entering the skin, the parasite migrates between the stratum germinativum and the stratum corneum, producing a serpiginous tract that is raised, firm, and vesiculo-bullous, surrounded by an area of erythema. The tracts are intensely pruritic and scratching may lead to secondary bacterial infections. Hypersensitivity reactions are a common feature of the disease, and may persist and generalize as in 2 patients in this series who had recurrent episodes of localized urticarial swelling. Even after the original rash had faded, 1 patient had allergic symptoms that included episodes of pharyngeal edema. These symptoms probably represented continued allergic reactions to larval proteins released by dying larvae after treatment.

The patients recalled no skin contact with ground surfaces outside the resort. Although no obvious fecal contamination of beaches or other areas was noted, several persons reported seeing cats in beach areas. The management of the resort chain was contacted and advised that local investigations should be carried out. Recommendations for control of probable sources of exposure emphasized removal of cats and dogs from public areas within the resort.

Reference

 Faust EC, Beaver PC, Jung RC. Animal agents and vectors of human disease. 4th ed. Philadelphia: Lea and Febiger, 1975:275-8.

Measles — U.S. Military


Measles incidence in the Armed Forces has dropped sharply in the United States as the result of a recently instituted measles vaccination program.

Military-related cases include cases among military personnel and cases among military dependents and civilians traced to military personnel with measles. Cases among military dependents were excluded when sources were not known to be military personnel, even though the cases may have occurred on a military base. For the past 2 years, CDC has kept records of cases of measles among military personnel, as well as the spread of measles from military personnel to the community. Military-related measles cases accounted for 245 (9.0%) of the 2,714 reported cases in the United States during the last half of 1979 and 1,025 (8.9%) of the 11,564* reported cases during the first half of 1980 (Figure 1).

On February 20, 1980, the Armed Forces Epidemiological Board issued a recommendation that "the Armed Forces establish a routine program for immunizing recruits

*Provisional data.

FIGURE 1. Reported measles cases related to the military,* by 6-month periods, July 1, 1979-June 13, 1981



*Military-related cases include cases among military personnel and cases among military dependents and civilians resulting from military personnel with measles. Cases in military dependents were excluded when sources were not known to be military personnel, even though the cases may have occurred on a military base.

Vol. 30/No. 25

MMWR

Measles - Continued

against measles" (1). This policy was quickly adopted. As a result, only 34 (1.8%) of the 1,866* reported cases during the second half of 1980 were military related. Of the 2,103* reported cases during the first 23 weeks of 1981, none was reported to be related to the military. The last reported military-related case was that of a military recruit with rash onset on August 17, 1980.

In 1980, the Armed Forces also adopted a policy requiring measles vaccination for attendance at Department of Defense (DOD) schools and day-care centers. All new teachers in DOD schools had to be vaccinated, and vaccination of volunteers and older staff members of schools and day-care centers was encouraged.

Reported by Col. AK Cheng, Office of the Surgeon General, U.S. Air Force; Col. GET Stebbing, Office of the Surgeon General, U.S. Army; Capt. RL Marlor, Navy Bur of Medicine and Surgery, U.S. Navy; Immunization Div, Center for Prevention Services, CDC.

Editorial Note: Measles has been a problem for the U.S. military at least since the Civil War, perhaps because of the unique epidemiologic environment of the military. During the first year of the Civil War, 21,676 cases and 551 deaths were reported among Union Troops (2). During World War I, approximately 30,000 U.S. soldiers per year were hospitalized with measles (3).

In the past few years, a number of military-related outbreaks have been documented (1,3-12) in which several patterns of measles transmission occurred. The most common pattern was endemic transmission on a single base from recruit to recruit in basic training (1,3-6). This ongoing transmission occasionally involved military dependents at day-care centers or schools (7-12), or civilian populations in communities surrounding military bases (11). In some states most of the cases were due to military-related transmission (4,7). A second pattern of transmission involved spread from 1 base to another when infected recruits finished basic training and were transferred for advanced training (1). A third transmission pattern involved spread to civilian populations in distant parts of the country as infected personnel went home on leave (1, 10, 11).

The data in Figure 1 indicate that the measles vaccination program instituted by the military has been highly successful. No military-related cases have been reported to CDC for the past 40 weeks. The Armed Forces have apparently succeeded in eliminating measles more than 2 years ahead of the national goal to eliminate indigenous measles.

The primary component of the current measles-elimination strategy is to achieve high percentages of immunity in the population through comprehensive vaccination programs. The results of the military program show that measles can be eliminated by this strategy. *References*

1. CDC. Measles associated with Fort Dix. MMWR 1980;29:166-7.

(Continued)

*Provisional data.

The Morbidity and Mortality Weakly Report, circulation 118,223, is published by the Centers for Disease Control, Atlanta, Georgia. The data in this report are provisional, based on weekly telegraphs to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday.

The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Send reports to: Attn: Editor, Morbidity and Mortality Weekly Report, Centers for Disease Control, Atlanta, Georgia 30333.

Send mailing list additions, deletions and address changes to: Attn: Distribution Services, Management Analysis and Services Office, 1-SB-419, Centers for Disease Control, Atlanta, Georgia 30333. When requesting changes be sure to give your former address, including zip code and mailing list code number, or send an old address label.

Measles - Continued

- Woodward JJ. Outlines of the chief camp diseases of the United States armies as observed during the present war. A practical contribution to military medicine. Philadelphia: Lippincott, 1863:267.
- 3. Cooch JW. Measles in U.S. Army recruits. Am J Dis Child 1962;103:264-6.
- 4. CDC. Measles Texas, 1978. MMWR 1978;27:489-90.
- 5. CDC. Measles and rubella at a military recruit training center Illinois. MMWR 1979;28:147-8.
- 6. CDC. Measles in Air Force recruits Texas. MMWR 1979;28:553-4.
- Schaffner W, Schluederberg AE, Byrne EB. Clinical epidemiology of sporadic measles in a highly immunized population. N Engl J Med 1968;279:783-9.
- 8. CDC. Measles and school immunizations Alaska. MMWR 1977;26:85-6.
- 9. CDC. Measles in military dependents Texas. MMWR 1979;28:58-60.
- 10. CDC. Measles importations into Montana 1977-1979. MMWR 1979;28:202-4.
- 11. CDC. Military to civilian transmission of measles -- Illinois, Nebraska. MMWR 1980;29:13-5.
- 12. CDC. Measles in a day-care center Washington. MMWR 1980;29:426-7.

☆U.S. Government Printing Office 1981 740-185/901

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE / CENTERS FOR DISEASE CONTROL ATLANTA, GEORGIA 30333 OFFICIAL BUSINESS

> Postage and Fees Paid U.S. Department of HHS HHS 396



Director, Centers for Disease Control William H. Foege, M.D. Director, Epidemiology Program Office Philip S. Brachman, M.D. Editor Michael B. Gregg, M.D. Managing Editor Anne D. Mather, M.A.

Mathematical Statistician Keewhan Chol, Ph.D.

316

HHS Publication No. (CDC) 81-8017

Redistribution using indicia is illegal.